Inverse, protean, and ligand-selective agonism: Matters of receptor conformation

FASEB Journal

Volumn 15, Issue 3, 2001, Pages 598-611

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Constitutive receptor activity; G protein coupled receptors; Inverse agonism; Receptor activation; Receptor theory

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND;

ALLOSTERISM; AMINO ACID SEQUENCE; BINDING SITE; GENE ACTIVATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TARGETING; RECEPTOR UPREGULATION; REVIEW; STEREOSPECIFICITY;

CELL LINE; DRUG DESIGN; GTP-BINDING PROTEINS; HUMANS; KINETICS; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, CELL SURFACE;

PROTEA;

EID: 0035083109     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0438rev     Document Type: Review

References (131)

1. Efficacy in drug receptor theory: Outdated concept or under-valued tool?
2. Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins
3. 2-adrenergic receptor activation of G-proteins: Evidence for a pre-coupled receptor/G-protein state
4. 1B-adrenergic receptor by all amino acid substitutions at a single site
5. 2-adrenergic receptor: Extending the ternary complex model
6. Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop
7. Expanding horizons for receptors coupled to G-proteins: Diversity and disease
8. Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis
9. Is there a 'lock' for all agonist 'keys' in 7TM receptors?
10. 1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint
11. The turning wheel: A study in steady states
12. The evolution of drug-receptor models: The cubic ternary complex model for G-protein coupled receptors
13. The cubic ternary complex receptor-occupancy model. I. Model description
14. The cubic ternary complex receptor-occupancy model. II. Understanding apparent affinity
15. The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy
16. Conformational substrates in proteins
17. The energy landscapes and motions of proteins
18. Model systems for the study of seven-transmembrane-segment receptors
19. Structure and function of G protein-coupled receptors
20. Specificity of receptor-G protein interactions: Searching for the structure behind the signal
21. Three cytoplasmic loops of rhodopsin interact with transducin
22. Multisite contacts involved in coupling of the β-adrenergic receptor with the stimulatory guanine-nucleotide-binding regulatory protein
23. Fluorescent labeling of purified β 2 adrenergic receptor: Evidence for ligand specific conformational changes
24. Constitutively active mutants of rhodopsin
25. Interaction of convulsive ligands with benzodiazepine receptors
26. In vitro characterization of benzodiazepine receptor agonists, antagonists, inverse agonists and agonist/antagonists
27. 1b-adrenergic receptor subtypes
28. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine
29. Histamin H2-receptor antagonists in peptic ulcer disease
30. 2-receptor antagonists
31. 2-receptor blockade
32. Inverse agonism of histamine H-2 antagonists accounts for up-regulation of spontaneously active histamine H-2 receptors
33. Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization
34. Mu and delta opioid receptors are differentially desensitized by the co-expression of β-adrenergic receptor kinase 2 and β-arrestin 2 in Xenopus oocytes
35. Constitutively active alpha-1b adrenergic receptor mutants display different phosphorylation and internalization features
36. 1D-adrenoceptors by agonists and inverse agonists
37. Receptor density and recycling affect the rate of agonist-induced desensitization of the μ-opioid receptor
38. Inverse agonism and the regulation of receptor number
39. 2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells
40. 2C receptor systems
41. Treatment with inverse agonists enhances baseline atrial contractility in transgenic mice with chronic beta2-adrenoceptor activation
42. Two C-protein oncogenes in human endocrine tumors
43. A heterozygous 4-bp deletion mutation in the Gsα gene (GNASI) in a patient with Albright hereditary osteodystrophy
44. Abnormalities in G-protein-coupled signal transduction pathways in human disease
45. 1B-adrenergic receptor enhances mitogenesis and tumorigenicity
46. The human vasoactive intestinal peptide receptor: Molecular identification by covalent cross-linking in colonic epithelium
47. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells
48. Molecular characteristics and evidence for internalization of vasoactive-intestinal-peptide (VIP) receptors in the tumoral rat-pancreatic acinar cell line AR 4-2J
49. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells
50. Functional vasoactive intestinal polypeptide (VIP) receptors in human neuroblastoma subclones that contain VIP precursor mRNA and release VIP-like substances
51. Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels
52. Cloning and expression of the human vasoactive intestinal peptide receptor
53. Modulation of the expression of the VIP receptor by serum factors on the human melanoma cell line IGR39
54. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors
55. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to minor cell membrane receptors
56. Localization of endocrine-related tumors with radiodinated analogue of somatostatin
57. Somatostatin-receptor imaging in the localization of endocrine tumors
58. Vasoactive intestinal peptide stimulates protein phosphorylation in a colonic epithelial cell line
59. The mitogenic effects of vasoactive neuropeptides on cultured smooth muscle cell lines
60. 2+, and protein kinase C
61. Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes
62. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts
63. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system
64. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth
65. Vasoactive intestinal peptide: Auto-crine growth factor in neuroblastoma
66. Use of constitutive G protein-coupled receptor activity for drug discovery
67. Secretin/vasoactive intestinal peptide-stimulated secretion of bombesin and gastrin releasing peptide from human small cell carcinoma of the lung
68. Mammalian bombesin receptors
69. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
70. Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma
71. 13.14] Bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo
72. Defects in G protein-coupled signal transduction in human disease
73. Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery
74. Human herpes virus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation
75. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor
76. Effect pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus
77. Inducible receptors
78. Stage-specific expression of P2Y receptors, ecto-apyrase and ecto-S'-nucleotidase in myeloid leukocytes
79. Pharmacological proteus?
80. Protean agonists: Keys to receptor-active states?
81. Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor
82. Inverse agonist activity of β-adrenergic antagonists
83. Differential signal transduction by five splice variants of the PACAP receptor
84. Comparative effects of receptor inactivation, 17β-estradiol and pertussis toxin on dopaminergic inhibition of prolactin-secretion in vitro
85. Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems
86. 11]SP analogues
87. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: Evidence for agonist-specific trafficking of intracellular responses
88. Agonist-receptor efficacy I: Mechanisms of efficacy and receptor promiscuity
89. Agonist-receptor efficacy II: Agonist-trafficking of receptor signals
90. Agonist-specific receptor conformations
91. Amino acids 356-372 constitute a Gi-activator sequence of the α 2-adrenergic receptor and have a Phe substitute in the G-protein-activator sequence motif
92. s activation
93. The use of stimulus-biased assay systems to detect agonist-specific receptor active-states: Implications for the trafficking of receptor stimulus by agonists
94. Signal transduction by calcitonin: Multiple ligands, receptors, and signaling pathways
95. 2-adrenergic receptor-Gs complex: Evidence for agonist-specific states
96. 2-adrenergic receptor/Gs interactions: Evidence for multiple receptor conformations
97. Contribution of serine residues to constitutive and agonist-induced signaling via the D2s dopamine receptor: Evidence for multiple, agonist-specific active conformations
98. μ Opiod receptor phosphorylation, desensitization, and ligand efficacy
99. Differential opioid agonist regulation of the mouse μ opioid receptor
100. 3 receptor by full and partial agonists
101. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor
102. Morphine activates opioid receptors without causing their rapid internalization
103. Agonist selective receptor states: The new level of selectivity?
104. HIV co-receptor down-regulation as antiviral principle: SDF-1-alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication
105. Phorbol esters and SDF-1 induce rapid endocytosis and down-regulation of the chemokine receptor CXCR4
106. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
107. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity
108. Viral quasi species and the problem of vaccine-escape and drug resistant mutants
109. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
110. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1-α contains mutations in the envelope gp120 but does not show a switch in coreceptor use
111. Similarities and differences in RANTES and (AOP)-RANTES-triggered signals: Implications for chemotaxis
112. Cooperation of multiple CCR5 co-receptors is required for infections by human immunodeficiency virus type 1
113. 1 cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain
114. Metabotropic glutamate receptor 5 is a disulfide-linked dimer
115. B receptor
116. B-receptor subtypes assemble into functional heterotrimeric complexes
117. BR2
118. 1 adenosine receptors
119. Dimerization of the δ opioid receptor
120. 2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation
121. Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells
122. Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function
123. Disulfide bonds in the extracellular calcium-polyvalent cation-sensing receptor correlate with dimer formation and its response to divalent cations in vitro
124. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
125. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin-like receptor
126. RAMPS: Accessory proteins for seven transmembrane domain receptors
127. Multiple amylin receptors arise from receptor activity modifying, protein interaction with the calcitonin receptor gene product
128. Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor
129. + exchange
130. Cloning and characterization of MUPPI, a novel PDZ domain protein